Huseyin Besiroglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huseyin Besiroglu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Emin Ozbek
Department of Urology, Istanbul University Cerrahpasa Medicine Faculty, Istanbul, Turkey
15 shared publications- Alper Otunctemur
Department of Urology, Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Turkey
14 shared publications Murat Dursun
Faculty of Medicine, Department of Urology, Istanbul University, Istanbul, Turkey
11 shared publications- Emin Ozbek
Department of Urology, Okmeydani Training and Research Hospital, Istanbul, Turkey
9 shared publications - Mustafa Erkoc
Department of Urology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey
8 shared publications - Emre Can Polat
Department of Urology, Cemil Tascioglu City Hospital, University of Health Sciences, Istanbul, Turkey
7 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 18
Micro-ultrasound versus mpMRI for targeted prostate biopsy: A systematic review, meta-analysis, and clinical integration
Background: In the era of precision prostate cancer diagnostics, the role of emerging imaging modalities requires redefinition within integrated diagnostic pathways. Micro-ultrasound (mUS) has emerged as a potential alternative to multiparametric magnetic resonance imaging (mpMRI) for targeted prostate biopsy; however, comparative evidence remains methodologically heterogeneous. Objectives: We aimed to re-evaluate the comparative detection performance of mUS versus mpMRI-targeted biopsy for clinically significant prostate cancer (csPCa), with particular attention to contemporary evidence and study design considerations. Design: Systematic review with meta-analysis. Data sources and methods: A systematic review of PubMed/MEDLINE, Web of Science, ScienceDirect, and the Cochrane databases was conducted up to February 28, 2026, in accordance with the PRISMA guidelines to identify studies comparing mUS- and mpMRI-targeted prostate biopsies. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The primary outcome was the pooled detection ratio (DR) for csPCa, defined as the ratio of detection rates between mUS- and mpMRI-targeted biopsy. Results: Fifteen studies comprising 2,512 patients were included. mUS-targeted biopsy detected csPCa in 654/2181 participants, compared to 691/2391 with mpMRI-targeted biopsy. The pooled DR for csPCa detection was 1.06 (95% CI 0.97–1.15; p=0.20), indicating no significant difference between modalities. Similarly, detection of clinically insignificant prostate cancer did not differ significantly (DR 0.89, 95% CI 0.72–1.10; p=0.28). Across studies, heterogeneity in design and potential within-patient correlations were identified as important contextual factors influencing interpretation. The inclusion of the OPTIMUM randomized trial provided complementary evidence from independently assigned diagnostic pathways, supporting the overall consistency of findings. Conclusion: No statistically significant difference was observed between mUS-targeted and mpMRI-targeted biopsies in the detection of clinically significant prostate cancer. Beyond a binary comparison, these findings support a shift toward integrated diagnostic pathways in which mUS may serve as a complementary or alternative tool depending on the clinical context. Further prospective and methodologically robust studies are needed to refine its role in precision prostate cancer diagnostics.
- 10 August 2026
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 18
Open AccessMicro-ultrasound versus mpMRI for targeted prostate biopsy: A systematic review, meta-analysis, and clinical integration
Background: In the era of precision prostate cancer diagnostics, the role of emerging imaging modalities requires redefinition within integrated diagnostic pathways. Micro-ultrasound (mUS) has emerged as a potential alternative to multiparametric magnetic resonance imaging (mpMRI) for targeted prostate biopsy; however, comparative evidence remains methodologically heterogeneous. Objectives: We aimed to re-evaluate the comparative detection performance of mUS versus mpMRI-targeted biopsy for clinically significant prostate cancer (csPCa), with particular attention to contemporary evidence and study design considerations. Design: Systematic review with meta-analysis. Data sources and methods: A systematic review of PubMed/MEDLINE, Web of Science, ScienceDirect, and the Cochrane databases was conducted up to February 28, 2026, in accordance with the PRISMA guidelines to identify studies comparing mUS- and mpMRI-targeted prostate biopsies. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The primary outcome was the pooled detection ratio (DR) for csPCa, defined as the ratio of detection rates between mUS- and mpMRI-targeted biopsy. Results: Fifteen studies comprising 2,512 patients were included. mUS-targeted biopsy detected csPCa in 654/2181 participants, compared to 691/2391 with mpMRI-targeted biopsy. The pooled DR for csPCa detection was 1.06 (95% CI 0.97–1.15; p=0.20), indicating no significant difference between modalities. Similarly, detection of clinically insignificant prostate cancer did not differ significantly (DR 0.89, 95% CI 0.72–1.10; p=0.28). Across studies, heterogeneity in design and potential within-patient correlations were identified as important contextual factors influencing interpretation. The inclusion of the OPTIMUM randomized trial provided complementary evidence from independently assigned diagnostic pathways, supporting the overall consistency of findings. Conclusion: No statistically significant difference was observed between mUS-targeted and mpMRI-targeted biopsies in the detection of clinically significant prostate cancer. Beyond a binary comparison, these findings support a shift toward integrated diagnostic pathways in which mUS may serve as a complementary or alternative tool depending on the clinical context. Further prospective and methodologically robust studies are needed to refine its role in precision prostate cancer diagnostics.
- Open Access
- 26 January 2025
- Published by Wiley in The Prostate
- Vol. 85 (6) , 541-557
The Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis
Background: Metastatic castration resistance prostate cancer (mCRPC) is a challenging disease with a significant burden of mortality and morbidity. Most of the patients attain resistance to the available treatments, necessitating further novel therapies in this clinical setting. Actinium 225 (225Ac) prostate‐specific membrane antigen (PSMA) radioligand therapy has emerged as a promising option and has been utilized for the last decade. Although a few meta‐analyses were performed on the efficacy and safety of 225Ac‐PSMA RLT in mCRPC patients, several current studies have been added to the literature since the latest meta‐analysis. We aimed to gather all individual studies to perform up‐to‐date meta‐analyses.Methods: We searched the literature using Pubmed‐Medline, Web of Science, Elsevier‐Sceince Direct, and Cochrane‐Central databases. The data for any PSA decline, over 50% PSA decline, overall survival (OS), progression‐free survival (PFS), and toxicity profile were captured from the studies eligible for meta‐analysis. We utilized the random effect model to generate pooled estimates.Results: The sixteen eligible studies contained 1102 patients. Sixty‐three percent of patients achieved more than 50% PSA decline, while 82% had any PSA decline after the completion of therapy. The pooled mean OS and PFS were 12.72 months (9.52–15.91) and 11.02 months (6.88–15.15), respectively. The most common adverse event was xerostomia, with a pooled proportion of 84%. Grade ≥ 3 anemia, thrombocytopenia, leucopenia, and nephrotoxicity were encountered in 9%, 5%, 4%, and 4% of the patients.Conclusions: 225Ac‐PSMA RLT is an efficacious and safe treatment for mCRPC. Future well‐designed randomized controlled studies comparing 225Ac‐PSMA RLT with other approved therapeutic options would better comprehend the exact role of this therapy in the treatment sequence of mCRPC.
- 26 January 2025
- Published by Wiley in The Prostate
- Vol. 85 (6) , 541-557
Open AccessThe Safety and Efficacy of Targeted Alpha Therapy, Ac‐225 Prostate‐Specific Membrane Antigen, in Patients With Metastatic Castration‐Resistant Prostate Cancer: A Systematic Review and Meta‐Analysis
Background: Metastatic castration resistance prostate cancer (mCRPC) is a challenging disease with a significant burden of mortality and morbidity. Most of the patients attain resistance to the available treatments, necessitating further novel therapies in this clinical setting. Actinium 225 (225Ac) prostate‐specific membrane antigen (PSMA) radioligand therapy has emerged as a promising option and has been utilized for the last decade. Although a few meta‐analyses were performed on the efficacy and safety of 225Ac‐PSMA RLT in mCRPC patients, several current studies have been added to the literature since the latest meta‐analysis. We aimed to gather all individual studies to perform up‐to‐date meta‐analyses.Methods: We searched the literature using Pubmed‐Medline, Web of Science, Elsevier‐Sceince Direct, and Cochrane‐Central databases. The data for any PSA decline, over 50% PSA decline, overall survival (OS), progression‐free survival (PFS), and toxicity profile were captured from the studies eligible for meta‐analysis. We utilized the random effect model to generate pooled estimates.Results: The sixteen eligible studies contained 1102 patients. Sixty‐three percent of patients achieved more than 50% PSA decline, while 82% had any PSA decline after the completion of therapy. The pooled mean OS and PFS were 12.72 months (9.52–15.91) and 11.02 months (6.88–15.15), respectively. The most common adverse event was xerostomia, with a pooled proportion of 84%. Grade ≥ 3 anemia, thrombocytopenia, leucopenia, and nephrotoxicity were encountered in 9%, 5%, 4%, and 4% of the patients.Conclusions: 225Ac‐PSMA RLT is an efficacious and safe treatment for mCRPC. Future well‐designed randomized controlled studies comparing 225Ac‐PSMA RLT with other approved therapeutic options would better comprehend the exact role of this therapy in the treatment sequence of mCRPC.
- Open Access
Is varicocoelectomy indicated in infertile men with isolated teratozoospermia? a systematic review and meta‐analysis
Background: Clinical palpable varicocoeles in conjunction with isolated teratozoospermia are rarely observed. Therefore, the effects of varicocoelectomy on sperm morphology are not clear. The aim of this meta‐analysis is to compile studies that assess the effectiveness of varicocoelectomy in isolated teratozoospermia to reach a more consistent and reliable conclusion.Material‐Methods: The present meta‐analysis was registered to PROSPERO (CRD42023467933). We utilized the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guideline to report the outcomes. Articles published before 1 October 2023 were included in the study. The search terms used were teratozoospermia, isolated teratozoospermia, varicocoelectomy for isolated teratozoospermia, and semen analysis after varicocoelectomy in isolated teratozoospermia.Results: We identified 1,013 studies in full publications or abstracts using the methodology and the search terms. Five studies were included for systematic review, while four were included for meta‐analysis. The five studies (10–14) included 348 patients aged 18–44 years. The pooled analysis revealed a significant improvement in sperm morphology in isolated teratozoospermia patients undergoing varicocoelectomy (Q = 199.42, p < 0.0001; I2 = 98.49%). The pooled analysis revealed no significant improvement in sperm concentration in isolated teratozoospermia patients undergoing varicocoelectomy (Q = 5.69, p = 0.058; I2 = 64.85%). Three of the examined studies provided information regarding pregnancy rate and it was high in all studies. According to the Newcastle–Ottowa scale (NOS) assessment, the total quality score of all studies was 7. The funnel plot test demonstrated a visible asymmetry, and Begg and Mazumdar's rank correlation test confirmed the publication bias (p = 0.04).Discussion: Varicocoelectomy can be an effective and reliable treatment option in patients with isolated morphology abnormalities and clinically palpable varicocoele.Conclusion: This meta‐analysis reported that varicocoelectomy may increase pregnancy rates by improving semen parameters in infertile men with isolated teratozoospermia, although this conclusion requires further evidence.
Open AccessIs varicocoelectomy indicated in infertile men with isolated teratozoospermia? a systematic review and meta‐analysis
Background: Clinical palpable varicocoeles in conjunction with isolated teratozoospermia are rarely observed. Therefore, the effects of varicocoelectomy on sperm morphology are not clear. The aim of this meta‐analysis is to compile studies that assess the effectiveness of varicocoelectomy in isolated teratozoospermia to reach a more consistent and reliable conclusion.Material‐Methods: The present meta‐analysis was registered to PROSPERO (CRD42023467933). We utilized the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guideline to report the outcomes. Articles published before 1 October 2023 were included in the study. The search terms used were teratozoospermia, isolated teratozoospermia, varicocoelectomy for isolated teratozoospermia, and semen analysis after varicocoelectomy in isolated teratozoospermia.Results: We identified 1,013 studies in full publications or abstracts using the methodology and the search terms. Five studies were included for systematic review, while four were included for meta‐analysis. The five studies (10–14) included 348 patients aged 18–44 years. The pooled analysis revealed a significant improvement in sperm morphology in isolated teratozoospermia patients undergoing varicocoelectomy (Q = 199.42, p < 0.0001; I2 = 98.49%). The pooled analysis revealed no significant improvement in sperm concentration in isolated teratozoospermia patients undergoing varicocoelectomy (Q = 5.69, p = 0.058; I2 = 64.85%). Three of the examined studies provided information regarding pregnancy rate and it was high in all studies. According to the Newcastle–Ottowa scale (NOS) assessment, the total quality score of all studies was 7. The funnel plot test demonstrated a visible asymmetry, and Begg and Mazumdar's rank correlation test confirmed the publication bias (p = 0.04).Discussion: Varicocoelectomy can be an effective and reliable treatment option in patients with isolated morphology abnormalities and clinically palpable varicocoele.Conclusion: This meta‐analysis reported that varicocoelectomy may increase pregnancy rates by improving semen parameters in infertile men with isolated teratozoospermia, although this conclusion requires further evidence.
- 5 February 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (5) , 2211-2221
The effect of transobturator tape surgery on female sexual function: a systematic review and meta-analysis
Purpose We aimed to review the literature regarding the effects of trans obturator tape surgery (TOT) on sexual functions in women with stress urinary incontinence (SUI) to reveal compact data and to reach more consistent and reliable results. Methods PRISMA statement was used in the current review. The databases of PubMed (Medline), Science Direct, and Cochrane Central Register of Controlled Trials were detected independently. We evaluated the studies comparing the preoperative and postoperative sexuality parameters related to the TOT procedure in females. Studies presenting the mean and standard deviation(SD) of global and sub-item Female Sexual Function Index(FSFI) were included in the current study. Results We identified 783 studies in full publications or abstract forms using the methodology above and the search terms. Finally, eight studies were included in the meta-analysis. The pooled analysis of the mean difference demonstrated that the total sexual function scores of the patients improved after TOT surgery. Conclusion The data collected from the current meta-analysis suggest that TOT surgery improves female sexual function.
- 5 February 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 309 (5) , 2211-2221
The effect of transobturator tape surgery on female sexual function: a systematic review and meta-analysis
Purpose We aimed to review the literature regarding the effects of trans obturator tape surgery (TOT) on sexual functions in women with stress urinary incontinence (SUI) to reveal compact data and to reach more consistent and reliable results. Methods PRISMA statement was used in the current review. The databases of PubMed (Medline), Science Direct, and Cochrane Central Register of Controlled Trials were detected independently. We evaluated the studies comparing the preoperative and postoperative sexuality parameters related to the TOT procedure in females. Studies presenting the mean and standard deviation(SD) of global and sub-item Female Sexual Function Index(FSFI) were included in the current study. Results We identified 783 studies in full publications or abstract forms using the methodology above and the search terms. Finally, eight studies were included in the meta-analysis. The pooled analysis of the mean difference demonstrated that the total sexual function scores of the patients improved after TOT surgery. Conclusion The data collected from the current meta-analysis suggest that TOT surgery improves female sexual function.
- 18 January 2024
- Published by Wiley in BJU International
- Vol. 134 (2) , 312
Re: ‘Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound’
- 18 January 2024
- Published by Wiley in BJU International
- Vol. 134 (2) , 312
Re: ‘Prostate cancer outcomes following whole‐gland and focal high‐intensity focused ultrasound’
- 1 September 2023
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 21 (7) , 370-377
Is There a Link Between Non-Alcoholic Fatty Liver Disease and Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms: A Systematic Review and a Meta-Analysis
Background: Prostatic growth has been thought to be the systemic manifestation of some metabolic derangements in recent studies. Nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, might be closely linked with benign prostate hyperplasia and lower urinary tract symptoms (BPH/LUTS). Several studies have been conducted regarding NAFLD and BPH/LUTS association. However, the results are yet to reach a clear conclusion. We aimed to gather these studies' results to make a more robust analysis through a systematic review and meta-analysis. Methods: We systematically searched Pubmed-Medline, Cochrane Library, and Science Direct databases. We excluded all experimental studies, case reports, and reviews. Our search was restricted to the English language. We used standard mean difference for BPH/LUTS-related parameters. We identified the study qualities by the Newcastle–Ottawa Scale. We conducted a publication bias analysis. Results: A total of six studies involving 7089 participants fulfilled the inclusion criteria. Our meta-analysis revealed that patients with NAFLD have larger prostate volume [0.553 (0.303–0.802), P ˂ 0.001; Q = 97.41; P-value for heterogeneity = P < 0.0001; I2 = 94.86%]. However, the summary effect size of the other parameters of BPH/LUTS (prostate-specific antigen and international prostate symptom score) computed in our meta-analysis did not yield significant results. Conclusions: The prostate size was larger in patients with NAFLD, but the meta-analysis did not reach a significant result for LUTS among the studies. These results should be tested with well-designed studies, in particular, to clarify the association of LUTS with NAFLD.
- 1 September 2023
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 21 (7) , 370-377
Is There a Link Between Non-Alcoholic Fatty Liver Disease and Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms: A Systematic Review and a Meta-Analysis
Background: Prostatic growth has been thought to be the systemic manifestation of some metabolic derangements in recent studies. Nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, might be closely linked with benign prostate hyperplasia and lower urinary tract symptoms (BPH/LUTS). Several studies have been conducted regarding NAFLD and BPH/LUTS association. However, the results are yet to reach a clear conclusion. We aimed to gather these studies' results to make a more robust analysis through a systematic review and meta-analysis. Methods: We systematically searched Pubmed-Medline, Cochrane Library, and Science Direct databases. We excluded all experimental studies, case reports, and reviews. Our search was restricted to the English language. We used standard mean difference for BPH/LUTS-related parameters. We identified the study qualities by the Newcastle–Ottawa Scale. We conducted a publication bias analysis. Results: A total of six studies involving 7089 participants fulfilled the inclusion criteria. Our meta-analysis revealed that patients with NAFLD have larger prostate volume [0.553 (0.303–0.802), P ˂ 0.001; Q = 97.41; P-value for heterogeneity = P < 0.0001; I2 = 94.86%]. However, the summary effect size of the other parameters of BPH/LUTS (prostate-specific antigen and international prostate symptom score) computed in our meta-analysis did not yield significant results. Conclusions: The prostate size was larger in patients with NAFLD, but the meta-analysis did not reach a significant result for LUTS among the studies. These results should be tested with well-designed studies, in particular, to clarify the association of LUTS with NAFLD.
- 21 March 2023
- Published by Wiley in BJU International
- Vol. 132 (1) , 112
Letter to the editor regarding the article ‘Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
- 21 March 2023
- Published by Wiley in BJU International
- Vol. 132 (1) , 112
Letter to the editor regarding the article ‘Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?
- 15 April 2021
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (4) , 1083-1084
Letter to the editor regarding the article “Trends in urinary stone composition in 23,182 stone analyses from 2011 to 2019: a high-volume center study in China”
- 15 April 2021
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (4) , 1083-1084
Letter to the editor regarding the article “Trends in urinary stone composition in 23,182 stone analyses from 2011 to 2019: a high-volume center study in China”
- 14 March 2020
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (8) , 1455-1463
Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma
Purpose Our aim was to evaluate the prognostic implications of a preoperative novel index, systemic immune inflammation index (SII) in patients undergoing surgery due to renal cell carcinoma. Methods A retrospective analysis of 176 patients who underwent radical nephrectomy and diagnosed with RCC was carried out. Systemic immune inflammation index, which is calculated by neutrophil x platelet/lymphocyte, and other inflammation indexes such as neutrophil/lymphocyte ratio, platelet/lymphocyte were included. The Kaplan–Meier analysis was plotted, and the groups were compared using a log-rank test. The ROC curve for the aforementioned inflammation indexes was plotted. Results SII (× 109/l) for lower and higher T stage group were 743.70 ± 587.55 and 907.06 ± 631.96, respectively, which is statistically significant (p = 0.01). Patients with higher Fuhrman grade (G3 and G4) were found to have higher SII (p = 0.001). SII 830 was demonstrated as the best cut-off value for overall survival. The optimal cut-off point for SII was defined as 850 for disease-specific survival. High SII scores were associated with poor overall survival in RCC patients (p = 0.034). However, no significant association was found for disease-specific survival (p = 0.29). Conclusions Systemic immune inflammation index was found to be associated with increased TNM stage and poor prognosis of RCC patients udergoing radical nephrectomy.
- 14 March 2020
- Published by Springer Nature in International Urology and Nephrology
- Vol. 52 (8) , 1455-1463
Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma
Purpose Our aim was to evaluate the prognostic implications of a preoperative novel index, systemic immune inflammation index (SII) in patients undergoing surgery due to renal cell carcinoma. Methods A retrospective analysis of 176 patients who underwent radical nephrectomy and diagnosed with RCC was carried out. Systemic immune inflammation index, which is calculated by neutrophil x platelet/lymphocyte, and other inflammation indexes such as neutrophil/lymphocyte ratio, platelet/lymphocyte were included. The Kaplan–Meier analysis was plotted, and the groups were compared using a log-rank test. The ROC curve for the aforementioned inflammation indexes was plotted. Results SII (× 109/l) for lower and higher T stage group were 743.70 ± 587.55 and 907.06 ± 631.96, respectively, which is statistically significant (p = 0.01). Patients with higher Fuhrman grade (G3 and G4) were found to have higher SII (p = 0.001). SII 830 was demonstrated as the best cut-off value for overall survival. The optimal cut-off point for SII was defined as 850 for disease-specific survival. High SII scores were associated with poor overall survival in RCC patients (p = 0.034). However, no significant association was found for disease-specific survival (p = 0.29). Conclusions Systemic immune inflammation index was found to be associated with increased TNM stage and poor prognosis of RCC patients udergoing radical nephrectomy.